Abstract
Alzheimer’s disease is associated with a relative decrease in the activity of the cholinergic system in the cerebral cortex and other areas of the brain (Bowen, 1981). This discovery has led to the development of agents designed to increase cholinergic function in the CNS. One such group of agents, the cholinesterase (ChE) inhibitors, increase the concentration of acetylcholine (ACh) by inhibiting one or more of the enzymes which hydrolyze it, i.e, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bowen DM (1981): The Molecular Basis of Neuropathology. Davison AN and Thompson RHS, eds. London: Edward Arnold.
Ellman GL, Courtney KD, Valentino A Jr., Featherstone RM (1961): Biochem. Pharmacol, 7:88–95.
Flicker DM, Dean RL, Watkins DL, Fisher SK, and Bartus RT (1983): Pharmacology, Biochemistry and Behavior, 18:973–981.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rogers, S.L., Yamanishi, Y., Yamatsu, K. (1991). E2020 — The Pharmacology of a Piperidine Cholinesterase Inhibitor. In: Becker, R., Giacobini, E. (eds) Cholinergic Basis for Alzheimer Therapy. Advances in Alzheimer Disease Therapy. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6738-1_33
Download citation
DOI: https://doi.org/10.1007/978-1-4899-6738-1_33
Publisher Name: Birkhäuser, Boston, MA
Print ISBN: 978-1-4899-6740-4
Online ISBN: 978-1-4899-6738-1
eBook Packages: Springer Book Archive